Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab, to Demonstrate Efficacy After Twelve Weeks of Treatment and to Assess Safety, Tolerability and Long-term Efficacy up to One Year in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis With or Without Psoriatic Arthritis Comorbidity
Brief Summary: The purpose of this study was to determine if secukinumab is effective and safe in the treatment of plaque type psoriasis


Options:
A: Arm Label: Risankizumab; Type: EXPERIMENTAL; Interventions: Drug: Risankizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Risankizumab; Assigned to Arm(s): Risankizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: CNTO 1959 (5 mg); Type: EXPERIMENTAL; Interventions: Drug: CNTO 1959 (5 mg) | Arm Label: CNTO 1959 (15 mg); Type: EXPERIMENTAL; Interventions: Drug: CNTO 1959 (15 mg) | Arm Label: CNTO 1959 (50 mg); Type: EXPERIMENTAL; Interventions: Drug: CNTO 1959 (50 mg) | Arm Label: CNTO 1959 (100 mg); Type: EXPERIMENTAL; Interventions: Drug: CNTO 1959 (100 mg) | Arm Label: CNTO 1959 (200 mg); Type: EXPERIMENTAL; Interventions: Drug: CNTO 1959 (200 mg) | Arm Label: Adalimumab (approved psoriasis dosing); Type: ACTIVE_COMPARATOR; Interventions: Drug: Adalimumab | Arm Label: Placebo to CNTO 1959 (100 mg); Type: PLACEBO_COMPARATOR; Interventions: Drug: CNTO 1959 (100 mg), Drug: Placebo | Intervention Type: DRUG; Name: CNTO 1959 (5 mg); Assigned to Arm(s): CNTO 1959 (5 mg) | Intervention Type: DRUG; Name: CNTO 1959 (15 mg); Assigned to Arm(s): CNTO 1959 (15 mg) | Intervention Type: DRUG; Name: CNTO 1959 (50 mg); Assigned to Arm(s): CNTO 1959 (50 mg) | Intervention Type: DRUG; Name: CNTO 1959 (100 mg); Assigned to Arm(s): CNTO 1959 (100 mg), Placebo to CNTO 1959 (100 mg) | Intervention Type: DRUG; Name: CNTO 1959 (200 mg); Assigned to Arm(s): CNTO 1959 (200 mg) | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): Adalimumab (approved psoriasis dosing) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo to CNTO 1959 (100 mg)
C: Arm Label: Secukinumab 150mg; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab 150 mg s.c. | Arm Label: Secukinumab 300mg; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab 300 mg s.c. | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Secukinumab 150 mg s.c.; Assigned to Arm(s): Secukinumab 150mg | Intervention Type: DRUG; Name: Secukinumab 300 mg s.c.; Assigned to Arm(s): Secukinumab 300mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Adalimumab (Humira); Type: ACTIVE_COMPARATOR; Interventions: Drug: Adalimumab (Humira) | Arm Label: Placebo Injection; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Injection | Arm Label: NB-UVB phototherapy; Type: ACTIVE_COMPARATOR; Interventions: Other: NB-UVB phototherapy | Intervention Type: DRUG; Name: Adalimumab (Humira); Assigned to Arm(s): Adalimumab (Humira) | Intervention Type: DRUG; Name: Placebo Injection; Assigned to Arm(s): Placebo Injection | Intervention Type: OTHER; Name: NB-UVB phototherapy; Assigned to Arm(s): NB-UVB phototherapy

Answer: C